Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2015-2022

$3,495.00

The Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2015-2022 report provides comprehensive understanding and unprecedented access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies.

Publication date
May 2022
Number of pages
400+
Product type
Research report
Available formats
PDF document
Report edition
3
SKU
CP22012

The Global Cancer Monoclonal Antibody Partnering 2015-2022 report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies.

  • Trends in cancer monoclonal antibody partnering deals
  • Most active companies in cancer monoclonal antibody partnering
  • Disclosed headlines, upfronts, milestones and royalties by stage of development
  • Cancer monoclonal antibody partnering contract documents
  • Top cancer monoclonal antibody deals by value

This report provides details of the latest cancer monoclonal antibody agreements announced in the healthcare sectors.

This report provides details of the latest antibody agreements announced in the healthcare sectors, covering:

  • Monoclonal antibodies
    • Murine mAb
    • Chimeric mAb
    • Humanized mAb
    • Human aAb

 

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all cancer monoclonal antibody partnering deals announced since Jan 2015, including financial terms where available, including links to online deal records of actual Cancer monoclonal antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of cancer monoclonal antibody dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in cancer monoclonal antibody dealmaking since 2015, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading cancer monoclonal antibody deals since 2015. Deals are listed by headline value, signed by big pharma, most active cancer monoclonal antibody dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in cancer monoclonal antibody dealmaking with a brief summary followed by a comprehensive listing of cancer monoclonal antibody deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of cancer monoclonal antibody partnering deals signed and announced since Jan 2015, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of cancer monoclonal antibody partnering deals signed and announced since Jan 2015. The chapter is organized by specific cancer monoclonal antibody technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by cancer monoclonal antibody partnering company A-Z, deal type definitions and cancer monoclonal antibody partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in cancer monoclonal antibody partnering and dealmaking since 2015.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of cancer monoclonal antibody technologies and products.

 

Key benefits

Global Cancer Monoclonal Antibody Partnering Terms & Agreements provides the reader with the following key benefits:

 

  • In-depth understanding of cancer monoclonal antibody deal trends since 2015
  • Access to headline, upfront, milestone and royalty data
  • Comprehensive access to over 600 actual cancer monoclonal antibody deals entered into by the world’s biopharma companies
  • Identify most active companies in cancer monoclonal antibody partnering
  • Insight into the terms included in a cancer monoclonal antibody agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals           
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies
  • Spot the emerging companies in the cancer monoclonal antibody area

 

Report scope

Global Cancer Monoclonal Antibody Partnering Terms & Agreements is intended to provide the reader with an in-depth understanding and access to cancer monoclonal antibody trends and structure of deals entered into by leading companies worldwide.

Cancer Monoclonal Antibody Partnering Terms & Agreements includes:

 

  • Trends in cancer monoclonal antibody dealmaking in the biopharma industry since 2015
  • Access to headline, upfront, milestone and royalty data
  • Access to over 600 cancer monoclonal antibody deal records
  • The leading cancer monoclonal antibody deals by value since 2015

 

In Cancer Monoclonal Antibody Partnering Terms & Agreements, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific oncology therapy target
  • Monoclonal antibody type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Cancer Monoclonal Antibody Partnering Terms & Agreements report provides comprehensive access to available deals and contract documents for over 600 cancer monoclonal antibody deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Global Cancer Monoclonal Antibody Partnering 2015-2022 provides the reader with the following key benefits:

 

  • In-depth understanding of cancer monoclonal antibody deal trends since 2015
  • Access to headline, upfront, milestone and royalty data
  • Comprehensive access to over 600 actual cancer monoclonal antibody deals entered into by the world’s biopharma companies
  • Identify the most active companies engaged in cancer monoclonal antibody partnering
  • Insight into the terms included in a cancer monoclonal antibody agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Executive Summary

 

Chapter 1 – Introduction

 

Chapter 2 – Trends in cancer monoclonal antibody dealmaking

 

2.1. Introduction
2.2. Cancer monoclonal antibody partnering over the years
2.3. Most active cancer monoclonal antibody dealmakers
2.4. Cancer monoclonal antibody partnering by deal type
2.5. Cancer monoclonal antibody partnering by therapy area
2.6. Deal terms for cancer monoclonal antibody partnering
2.6.1 Cancer monoclonal antibody partnering headline values
2.6.2 Cancer monoclonal antibody deal upfront payments
2.6.3 Cancer monoclonal antibody deal milestone payments
2.6.4 Cancer monoclonal antibody royalty rates

 

Chapter 3 – Leading cancer monoclonal antibody deals

 

3.1. Introduction
3.2. Top cancer monoclonal antibody deals by value

 

Chapter 4 – Most active cancer monoclonal antibody dealmakers

 

4.1. Introduction
4.2. Most active cancer monoclonal antibody dealmakers
4.3. Most active cancer monoclonal antibody partnering company profiles

 

Chapter 5 – Cancer monoclonal antibody contracts dealmaking directory

 

5.1. Introduction
5.2. Cancer monoclonal antibody contracts dealmaking directory

 

Chapter 6 – Cancer monoclonal antibody dealmaking by technology type

 

Monoclonal antibodies
Chimeric mAb
Humanized mAb
Human mAb
Murine mAb

 

Appendices

Appendix 1 – Cancer monoclonal antibody deals by company A-Z

Appendix 2 – Cancer monoclonal antibody deals by stage of development

Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation

Appendix 3 – Cancer monoclonal antibody deals by deal type

Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Co-promotion
CRADA
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Loan
Manufacturing
Marketing
Material transfer
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination

Appendix 4 – Cancer monoclonal antibody deals by therapy area

Appendix 5 – Deal type definitions

Appendix 6 – Further reading on dealmaking

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from Current Partnering


Table of figures

Figure 1: Therapeutic antibody definitions
Figure 2: Cancer monoclonal antibody partnering since 2015
Figure 3: Active cancer monoclonal antibody dealmaking activity since 2015
Figure 4: Cancer monoclonal antibody partnering by deal type since 2015
Figure 5: Cancer monoclonal antibody partnering by disease type since 2015
Figure 6: Cancer monoclonal antibody deals with a headline value
Figure 7: Cancer monoclonal antibody deals with an upfront value
Figure 8: Cancer monoclonal antibody deals with a milestone value
Figure 9: Cancer monoclonal antibody deals with a royalty rate value
Figure 10: Top cancer monoclonal antibody deals by value since 2015
Figure 11: Most active cancer monoclonal antibody dealmakers since 2015

Pricing options

  • $3,495: single-user
  • $5,245: multi-user
  • $10,495: single site license
  • $17,495: global site license

 

A full explanation of license type definitions can be found here.

 

Our guarantee

 

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

 

Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)

 

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

 

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.

 

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

 

Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

3D Medicines, 3SBio, 4D Pharma, Abbvie, AbClon, Abdul Latif Jameel Health, Abmuno Therapeutics, Abpro, Abveris, Abzena, Accord Healthcare, Acerta Pharma, Adagene, Adaptimmune, Adaptive Biotechnologies, Adium Pharma, Adlai Nortye, Aduro BioTech, Advaxis, Aeglea BioTherapeutics, AffaMed Therapeutics, Affimed Therapeutics, Affinita Biotech, AGC Biologics, Agenus Bio, Ajinomoto, Akeso Biopharma, Alligator Bioscience, Alloy Therapeutics, Almac Group, Alphamab Biopharmaceuticals, Alpine Immune Sciences, Alvogen, Alvotech, ALX Oncology, Ambrx, Amgen, Amneal Pharmaceuticals, Antengene, Antigen Express, Apceth, Aperion Biologics, Apexigen, Aptevo Therapeutics, Arch Oncology, Arcus Biosciences, argenx, Array Biopharma, Ascenion, Ascentage Pharma, Asieris MediTech, Aslan Pharma, Astellas Pharma, Astex Pharmaceuticals, AstraZeneca, Atara Biotherapeutics, Athenex, Atlab Pharma, Atlante Biotech, Atlas Antibodies, ATP, aTyr Pharma, Aulos Bioscience, AVEO Oncology, Aytu BioPharma, Basilea Pharmaceutica, Bavarian Nordic, Baxalta, Bayer, BeiGene, Beijing InnoCare Pharma, BerGenBio, Betta Pharmaceuticals, Binex, Bio-Manguinhos/Fiocruz, Bio-Thera Solutions, BioAtla, Biodesix, Bio Farma, BioInvent, BiolineRX, Biolojic Design, BioMarker Strategies, Biomm, Biomunex Pharmaceuticals, Bioncotech Therapeutics, Biond Biologics, BioNTech, Biosion, Biothera Pharmaceuticals, BioXcel, Blackstone, BliNK Biomedical, BliNK Therapeutics, Boehringer Ingelheim, Bolt Biotherapeutics, Boston Immune Technologies and Therapeutics, Bpifrance, BridgeBio Pharma, Bright Peak Therapeutics, Bristol-Myers Squibb, C-Bridge Capital, California Institute for Regenerative Medicine, Calithera Biosciences, Cancer Australia, Cancer Focus Fund, Cancer Prevention and Research Institute of Texas, Cancer Research Technology, Cancer Research UK, CanCure, Candel Therapeutics, Cantargia, Caris Life Sciences, Catalent, CBT Pharmaceuticals, CDI Laboratories, Celgene, Celldex Therapeutics, Cellectis, Cell Signaling Technology, Celltrion, Celularity, Centre for Drug Research and Development (CDRD), CG Oncology, Champions Oncology, Checkmate Pharmaceuticals, Checkpoint Therapeutics, Chi-Med, Chiome Bioscience, Cilag AG, Cipla, City of Hope Comprehensive Cancer Center, Clinica Universidad Navarra, Clovis Oncology, CMAB Biopharma, Coherus Biosciences, Cold Genesys, Columbia University, Compugen, Convergent Therapeutics, Corvus Pharmaceuticals, Covalab, Creative Biolabs, Crescendo Biologics, Crown Bioscience, CStone Pharmaceuticals, Cue Biopharma, Cullinan Oncology, Curative Biotechnology, Cytodyn, Cytovation, Daiichi Sankyo, Dako, Debiopharm, Diaprost, Distributed Bio, DNAtrix, Dr. Reddy's Laboratories, Dynavax Technologies, eFFECTOR Therapeutics, Eisai, Elevation Oncology, Eleven Biotherapeutics, Eli Lilly, ElsaLys Biotech, EMD Millipore, EMD Serono, Enumeral Biomedical, Enzolytics, EpiThany, EQRx, Essex Bio-Technology, Eucure Biopharma, Eureka Therapeutics, Eurofarma, European Union Regional Development Fund, EUSA Pharma, Eutilex, Evaxion Biotech, Everest Medicines, Exelixis, F-Star Therapeutics, FarmaMondo Group, Faron Pharmaceuticals, Fate Therapeutics, Five Prime Therapeutics, FLX Bio, Forty Seven, Fosun Kite Biotechnology, Fred Hutchinson Cancer Research Center, Fuhong Hanlin, Fusion Pharmaceuticals, Galaxy Biotech, Galecto, Genentech, Genexine, Genmab, Genome and Company, Genor Biopharma, Genprex, GenScript Biotech, Georgetown University, Gilead Sciences, GlaxoSmithKline, Glenmark Pharmaceuticals, Glycotope Biotechnology, Glythera, Goodwin Biotechnology, Gossamer Bio, Gradalis, Gritstone Bio, H-Immune, H3 Biomedicine, HaemaLogiX, Halozyme Therapeutics, Harbour Biomed, Heidelberg Pharma, Henlius Biotech, HiberCell, Highlight Therapeutics, Hikma Pharmaceuticals, Hisun BioRay, Hoffmann La Roche, Hookipa Pharma, Hospira, Hualan Genetic, Humanigen, Hummingbird Bioscience, Hutchison MediPharma, Huyabio International, I-mab, i2 Pharmaceuticals, iBio, IcanoMAB, iDD Biotech, Idera Pharmaceuticals, ImCheck Therapeutics, ImClone Systems, Immatics Biotechnologies, Immix Biopharma, Immune Design, ImmuneOncia Therapeutics, Immune Pharmaceuticals, Immunitas Therapeutics, ImmunoChina Pharmaceuticals, Immunocore, ImmunoGen, Immunomedics, Immunovaccine, Immutep, IMPACT Therapeutics, Imugene, IMV, Incyte, Infinity Pharmaceuticals, Innate Pharma, Innovent Biologics, Inserm, Inserm Transfert, Inspirna, Institut Bergonie, Institute of Biophysics, Integral Molecular, Intensity Therapeutics, Invenra, InxMed, IO Biotech, IONTAS, Ipsen, IRBM, ISA Pharmaceuticals, Isotopia Molecular Imaging, Italian Association for the Study of Pancreas, iTeos Therapeutics, Janssen Biotech, Janssen Research & Development, Jazz Pharmaceuticals, JHL Biotech, Jiangsu Alphamab, Jiangsu Hansoh Pharmaceutical, Jiangsu Hengrui Medicine, Jiangsu Hengrui Pharmaceuticals, Johns Hopkins University, Johnson & Johnson Innovation, Johnson Matthey, Jounce Therapeutics, Juno Therapeutics, Junshi Biosciences, KAHR Medical, Kalbe Genexine Biologics, Kelun-Biotech Biopharmaceutical, Kiniksa Pharmaceuticals, Kintor, Kite Pharma, Kitov Pharma, Kolltan Pharmaceuticals, Kymab, Laekna, Lassen Therapeutics, Leads Biolabs, Leap Therapeutics, Leica Biosystems, LEO Pharma, Les Laboratoires Servier, Leukemia & Lymphoma Society, LG Life Sciences, Linnaeus Therapeutics, Livzon Mabpharm, Lonza, Lumos Pharma, Lupagen, Lyvgen Biopharma, MAB Discovery, Mabion, mAbsolve, MabVax Therapeutics, mAbXience, Macquarie University, Macrogenics, MAIA Biotechnology, Manhattan BioSolutions, Mapp Biopharmaceutical, Massachusetts General Hospital, Mayo Clinic, MD Anderson Cancer Center, Medical Research Council, MedImmune, Memorial Sloan Kettering Cancer Center, Merck and Co, Merck KGaA, Merck Sharpe & Dohme, Mereo BioPharma, Merrimack Pharmaceuticals, Merus, MicroConstants, Minomic, Mitra Biotech, Mitsubishi Tanabe Pharma, Molcure, Moleculin Biotech, MorphoSys, Morphotek, Mount Sinai Health System, MSD, Mundipharma, Mustang Bio, Mylan Laboratories, Mylan Pharmaceuticals, Myriad Genetics, NantBioScience, NantCell, NantKwest, NantWorks, Nascent Biotech, National Cancer Institute, National Center for Tumor Diseases, National Comprehensive Cancer Network (NCCN), National Institutes of Health, National University Cancer Institute, Navrogen, NCIC Clinical Trials Group, Nectin Therapeutics, Nektar Therapeutics, Nelum Pharma, NeoBiotechnologies, NeoImmuneTech, Neoleukin Therapeutics, Neon Therapeutics, NETRIS Pharma, Neuroblastoma and Medulloblastoma Translational Research, Nexvet, NGM Biopharmaceuticals, NKMax America, Nordic Society of Gynaecological Oncology, Northern Biologics, NovalGen, Novartis, Novelogics Biotechnology, NovImmune, Novocure, Noxopharm, Noxxon Pharma, Numab, OBI Pharma, Olivia Newton-John Cancer Research Institute, OncoCare Therapeutics, OncoImmune, Oncologie, Oncolytics Biotech, OncoMed Pharmaceuticals, OncoQuest, OncoSec Medical, Oncternal Therapeutics, Oncurious, OncXerna Therapeutics, Ono Pharmaceutical, Open Monoclonal Technology, OSE Immunotherapeutics, Oxford BioTherapeutics, Panacea Pharmaceuticals, Pascal Biosciences, Patheon, PDS Biotechnology, Pelican Therapeutics, Peregrine Pharmaceuticals, Personal Genome Diagnostics, Personalis, Pfizer, Phanes Therapeutics, PharmAbcine, Pharmapark, Pierre Fabre, Pionyr Immunotherapeutics, PlantForm, PlantPraxis Biotecnologia, Pneuma Respiratory, POINT Biopharma, Poseida Therapeutics, Precision Biologics, Precision BioSciences, Prestige BioPharma, ProBioGen, Progenetics, Progenics Pharmaceuticals, Promega, ProtoKinetix, PT Etana Biotechnologies, PULSALYS, PureTech Health, Pyxis Oncology, QBiotics, Qiagen, Quantum Leap Health Care Collaborative, Queensland Institute of Medical Research (QIMR), Quest PharmaTech, Qurient, Radboud University Nijmegen Medical Centre, Rakuten Medical, RefleXion Medical, Regeneron Pharmaceuticals, Regnum, Rentschler Biotechnologie, Replimune, Rexahn Pharmaceuticals, Roche, Rockefeller University, Roswell Park Cancer Institute, Royalty Pharma, RubrYc Therapeutics, Saccharo, Samsung Bioepis, Samsung Biologics, Samyang Biopharmaceuticals, Sandoz, Sanofi, Sanofi-Aventis, Sarah Cannon Research Institute, SATT Sud-Est, Scandion Oncology, Schrodinger, SciClone Pharmaceuticals, Scripps Research Institute, Sea Lane Biotechnologies, Seattle Genetics, Seismic Bio, Selecxine, Selexis, SELLAS Life Sciences Group, Sensei Biotherapeutics, Seven and Eight Biopharmaceuticals, SevenScore Pharmaceuticals, Sharp HealthCare, Shenogen Pharma, Shenzhen Chipscreen Biosciences, Silverback Therapeutics, Simcere Pharmaceuticals, Sirnaomics, Sorrento Therapeutics, Sosei Heptares, SOTIO, Spanish National Research Council, Specialized Medical Services-oncology, Spring Bank Pharmaceuticals, Stand Up To Cancer, Strata Oncology, Sud Investments, Surface Oncology, Swedish Orphan Biovitrum, Swixx Biopharma, Symphogen, Syndax Pharmaceuticals, Synlogic, Syros Pharmaceuticals, T-Cure Bioscience, Taiho, Takeda Pharmaceutical, Talem Therapeutics, TARIS Biomedical, Tavotek Biotherapeutics, TCR2 Therapeutics, Telix Pharmaceuticals, Tempest Therapeutics, TeneoBio, Tesaro, Tessa Therapeutics, Tetragenetics, TetraLogic Pharmaceuticals, Teva Pharmaceutical Industries, TG Therapeutics, Theradiag, Theranyx, Thermo Fisher Scientific, ThromboGenics, TILT Biotherapeutics, Tiziana Life Sciences, Tizona Therapeutics, Tmunity Therapeutics, Torque Therapeutics, TPG Capital, TRACON Pharmaceuticals, Transcenta, Transgene, TransPerfect Life Sciences, TransThera, Trianni, Trieza Therapeutics, Trio Pharmaceuticals, Turgut Ilaclari, Twist Bioscience, UbiVac, UCB, UMass Memorial Medical Center, Universite Claude Bernard Lyon, University of Bergen, University of British Columbia, University of California, San Diego, University of California Los Angeles, University of California San Francisco, University of Cologne, University of Massachusetts Medical School, University of Melbourne, University of Minnesota, University of New Mexico, University of Nottingham, University of Wisconsin Carbone Cancer Center (UWCCC), Unum Therapeutics, UroGen Pharma, Vaccinex, Valneva, Vaximm, Vcell Healthcare, Vedanta Biosciences, Verastem, Verseau Therapeutics, VIB, Viela Bio, Viralytics, Vyriad, Werewolf Therapeutics, Wilex, WindMIL Therapeutics, Wuxi Shuangliang Biotechnology, XBiotech, Xencor, Xilio Therapeutics, Xoma, Y-Biologics, Y-mAbs Therapeutics, Yale University, ZAI Laboratory, Zenoaq, Zhejiang Bossan Pharmaceutical, Zhejiang Hisun Pharmaceutical, Zhejiang Huahai Pharmaceutical, Zumutor Biologics, Zydus Cadila

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• CRADA
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.

We found other products you might like!